And AbbVie and Genmab scoop their ASH presentation with new data.
ApexOnco Front Page
Recent articles
The company adds royalty aggregation to its R&D business.
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
Syndax’s Revuforj beats Kura in NPM1-mutated AML.
The group is expanding its mRNA-4359 trial to include first-line melanoma.
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
The second-line Litespark-011 and adjuvant Litespark-022 trials are apparently hits.
